Navigation Links
Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
Date:11/5/2007

FORT LAUDERDALE, Fla., Nov. 5 /PRNewswire-FirstCall/ Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced that CT Laser Mammography (CTLM(R)) results were exhibited at the 4th Congress of the World Society for Breast Health in Tianjin, China, October 18th - 21st.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

The Congress attracted more than 500 breast health experts from 23 different countries and offered 29 clinical and academic presentations on breast health, including epidemiology, screening, diagnosis, prevention, and the treatment of breast cancer.

IMDS local representatives exhibited clinical imaging cases from international sites. Several meeting attendees visited the recent CTLM installation at the Tianjin Medical University Cancer Institute and Hospital, where clinical studies are now underway.

Explained Tim Hansen, IMDS Chief Executive Officer: "Exhibiting at the Congress allowed us to support our global commercialization efforts while highlighting the research that is being conducted at the Tianjin Medical University Cancer Institute and Hospital as well as at Beijing Friendship Hospital. Having an operating CTLM system in the same city helped reinforce our messages to those seriously considering our approach. China represents a significant market; CTLM solves real clinical problems for these users and their patients."

The Congress was organized by the World Society for Breast Health, the Chinese Oncology Society and the Chinese Medical Association, along with the Tianjin Medical University Cancer Institute and Hospital, which served as the local organizer. Previous World Society for Breast Health Congresses have been held in Istanbul, Turkey; Budapest, Hungary; and Tokyo, Japan.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: http://www.imds.com.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:

Rick Lutz

404-261-1196

lcgroup@mindspring.com

Media Contact:

Elizabeth Williams

(954) 581-9800

williams@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
2. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
3. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
4. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
5. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
8. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
9. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, Embodied ... Startups pitch competition and came away with $25,000 ... is described by Forbes as "entering the life of ... Association as teaching "empathy to medical professionals in an ... was recently named a finalist for the Department of ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... ... appointment of Mike Finnegan to the position of Executive Vice President, Sales and ... in healthcare technology, telehealth and medical device sales leadership. He has received industry ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... many of the health care industry’s hospitals and provider groups, has announced that ... for select customers. Parasail Health is a San Francisco health-finance startup that has ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... reach a staggering $6.81 billion by the year 2024 according to a new report. ... rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is ... PTSD. Yet less than 20% will receive adequate care due to lack of effective ... receive any care at all. And left untreated, veterans are at an increased risk ...
Breaking Medicine News(10 mins):